These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24597542)

  • 41. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
    Cai Y; Wang R; Liang B; Bai N; Liu Y
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1162-72. PubMed ID: 21173186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tigecycline: a review of properties, applications, and analytical methods.
    da Silva LM; Nunes Salgado HR
    Ther Drug Monit; 2010 Jun; 32(3):282-8. PubMed ID: 20431506
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year experience with tigecycline in treating serious infections in severely burned patients.
    Lipový B; Rihová H; Hanslianová M; Brychta P
    Acta Chir Plast; 2009; 51(3-4):69-71. PubMed ID: 20514890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies.
    Bai XR; Liu JM; Jiang DC; Yan SY
    J Chemother; 2018 May; 30(3):172-178. PubMed ID: 29405898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
    Teras J; Gardovskis J; Vaasna T; Kupcs U; Pupelis G; Dukart G; Dartois N; Jouve S; Cooper A;
    J Chemother; 2008 Oct; 20 Suppl 1():20-7. PubMed ID: 19036671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
    Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
    Fraise AP
    J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tigecycline: clinical evidence and formulary positioning.
    Nathwani D
    Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Yahav D; Lador A; Paul M; Leibovici L
    J Antimicrob Chemother; 2011 Sep; 66(9):1963-71. PubMed ID: 21685488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline.
    Nicolau DP
    Expert Opin Pharmacother; 2009 May; 10(7):1213-22. PubMed ID: 19405794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
    DeBellis HF; Jones MC; Kincaid SE
    J Pharm Pract; 2012 Dec; 25(6):569-75. PubMed ID: 23065389
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Excess deaths associated with tigecycline after approval based on noninferiority trials.
    Prasad P; Sun J; Danner RL; Natanson C
    Clin Infect Dis; 2012 Jun; 54(12):1699-709. PubMed ID: 22467668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tigecycline: a new glycylcycline antimicrobial agent.
    Kasbekar N
    Am J Health Syst Pharm; 2006 Jul; 63(13):1235-43. PubMed ID: 16790575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The yield of tigecycline in the treatment of community-acquired pneumonia].
    Cilli A
    Tuberk Toraks; 2013; 61(2):155-61. PubMed ID: 23875595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What role for tigecycline in infections?
    BMJ Group
    Drug Ther Bull; 2008 Aug; 46(8):62-4. PubMed ID: 18687585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.